salirasib
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00531401)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Transforming protein p21/H-Ras-1INHIBITOR
HRAS inhibitor
- RASINHIBITOR
RAS inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)=CCC/C(C)=C/CC/C(C)=C/CSc1ccccc1C(=O)O- Mol. weight
- 358.55 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL23293 ↗
Also known as
- farnesylthiosalicylic acid
- fts
- fts
- salirasib
- salirasib
- salirasib
- salirasib
- salirasib
- s-farnesylthiosalicylic acid
- s-trans,trans-farnesylthiosalicylic acid
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00531401 | Phase 2 | Sep 1, 2007 | Advanz Pharma, Cornell University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Advanz Pharma | For profit | 1 | 1 | 1 | 2007 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2007 |
2 organizations
Page 1 / 1